Form 4: Vir Bio CFO Sells Shares for Tax Obligations

Vir Biotechnology's EVP & CFO, Jason O'Byrne, sold 6,799 shares of common stock at $5.557 per share to cover tax withholding related to restricted stock unit vesting.

Summary

• Jason O'Byrne, Executive Vice President & Chief Financial Officer of Vir Biotechnology, Inc. (VIR), reported a transaction involving the company's common stock.
• On November 17, 2025, O'Byrne disposed of 6,799 shares of common stock at a price of $5.557 per share.
• The sale was an automatic transaction to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
• This transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Jason O'Byrne beneficially owns 110,701 shares of common stock.
• The reported beneficial ownership includes 2,500 shares of common stock acquired by O'Byrne on May 30, 2025, through an employee stock purchase program.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale of shares to cover tax withholding obligations associated with RSU vesting, often pre-scheduled under a Rule 10b5-1 plan. This type of transaction is neutral in sentiment as it does not indicate a change in management's outlook or a discretionary decision to reduce holdings.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing reports a routine insider transaction, specifically a non-discretionary sale of shares to cover tax obligations related to restricted stock unit vesting. Such transactions are common across all industries for executives receiving equity compensation and do not typically reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in the executive's confidence or the company's fundamentals.

Key Dates

Recommendation

The reported transaction is a non-discretionary sale of shares by an executive to cover tax obligations related to restricted stock unit vesting, which is a common and routine event. It does not reflect a change in management's outlook or a discretionary decision to reduce holdings, thus it has no material impact on the investment thesis for Vir Biotechnology. A 'hold' recommendation is appropriate as this filing does not provide new information to alter an existing investment stance.

Keywords

Vir Biotechnology, VIR, Form 4, Insider Transaction, Stock Sale, CFO, Jason O'Byrne, Tax Withholding, RSU Vesting, Rule 10b5-1